Acadian Asset Management
TGTX icon

Acadian Asset Management’s TG Therapeutics TGTX Stock Holding History

Acadian Asset Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$509K Buy
9,276
+616
+7% +$25.2K ﹤0.01% 1440
2026
Q1 		$287K Sell
8,660
-2,113
-20% -$63K ﹤0.01% 1491
2025
Q4 		$321K Buy
+10,773
New +$352K ﹤0.01% 1420
2024
Q4 		– Sell
-8,226
Closed -$192K – 2157
2024
Q3 		$192K Buy
+8,226
New +$180K ﹤0.01% 1383

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Acadian Asset Management's TGTX Position: Q2 2026 in Review

Acadian Asset Management increased its TG Therapeutics (TGTX) stake by 7.1% in Q2 2026, buying an estimated $25.2K and bringing the position to 9,276 shares worth $509K. The position accounts for ﹤0.01% of the portfolio, ranked #1440.

Acadian Asset Management first reported a position in TGTX in Q3 2024 and has held it in 4 quarters since. 430 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Acadian Asset Management held 9,276 shares of TG Therapeutics worth $509K as of Q2 2026.
  • Acadian Asset Management bought 616 TG Therapeutics shares in Q2 2026, an estimated $25.2K.
  • TG Therapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #1440 holding.
  • Acadian Asset Management first reported a position in TG Therapeutics in Q3 2024 and has held it in 4 quarters since.
  • 430 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.